Paclitaxel is under clinical development by Lipac Oncology and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According to GlobalData, Phase II drugs for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) have a 19% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Paclitaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Paclitaxel overview
Paclitaxel (TBC-1002) is under development for the treatment of non-muscle-invasive bladder cancer (NMIBC), noninvasive papillary carcinoma of bladder, transitional cell carcinoma (TCC) of the bladder, upper tract urothelial carcinoma, stage II/III ovarian cancer, mesothelioma, malignant pleural effusion and peritoneal cancer. The drug candidate is administered through intravesical route. It constitutes pro-liposomal powder formulation of paclitaxel. It acts by targeting tubulin. It is developed based on pro-liposomal platform technology.
Lipac Oncology overview
Lipac Oncology is a pharmaceutical company focused on advancing the development of new investigational therapies to treat intracavitary cancers. The company’s lead drug candidate is LiPax, is a locally delivered formulation of the well-established chemotherapy drug. Its lead drug is used to treat non-muscle invasive bladder cancer (NMIBC), upper tract urothelial carcinoma (UTUC), intraperitoneal carcinoma, stage II and III ovarian cancer, and mesothelioma and malignant pleural effusion. The company also conduct various phases of clinical trials like pre-clinical studies, phase I and phase II. It also carries out research and development activities. Lipac Oncology is headquartered in Pomona, California, the US.
For a complete picture of Paclitaxel’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
